CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project aims to develop new adjuvants for vaccines by studying a novel cationic lipid that activates immune pathways. The goal is to create safe and effective adjuvants that can enhance vaccine responses without the toxicity associated with current formulations.
Vaccine research has highlighted the need for effective adjuvant formulations that elicit strong, safe and protective cellular immune responses.
Through recognition by Toll-like receptors (TLRs), adjuvants brings the immune system in a “state of emergency” required for an efficient vaccine formulation.
Knowledge of TLR-mediated signalling, therefore, could lead to rational adjuvant design for vaccines.
Bacterial lipopolysaccharides (LPS), major components of the outer membrane of Gram-negative b…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
